CompletedNot applicableNCT05059691

Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy

This study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional fluoroscopy. Transbronchial cryobiopsy is a procedure to collect lung tissue. The main side effect seen after a transbronchial cryobiopsy is pneumothorax (air leaking out of the lung, which may cause a completely or partially collapsed lung). The standard imaging scans used during this procedure are 2-dimensional (like a photo), which can make it difficult for the doctor to know exactly where the biopsy tool is during the procedure. If the exact location of the device is not clear, a patient can be at a higher risk of pneumothorax. Using a 3-dimensional imaging technique may help to decrease the risk of pneumothorax during transbronchial cryobiopsy.

Checked against the public recordLast updated May 15, 2023 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorM.D. Anderson Cancer Center
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
M.D. Anderson Cancer Center
Interventions being studied
Other: Electronic Health Record Review; Procedure: Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Age 18 years or older * Presence of an intraparenchymal lung lesion for which cryobiopsy is deemed the most appropriate method of biopsy * Ability to provide informed consent Exclusion Criteria: * Acute respiratory failure (defined as oxygen requirement \> 4 L/min by nasal cannula above baseline, or need for any intervention to support ventilation and/or gas exchange for any duration, including invasive and non-invasive positive pressure ventilation, high-flow therapy, non-rebreather mask, or Venturi mask) * Intensive care unit (ICU) admission * Forced vital capacity (FVC) \< 50% or diffusing capacity of the lung for carbon monoxide (CO) (DLCO) \< 35% (if pulmonary function tests are available) * Known or suspected pulmonary hypertension (defined as elevated right ventricular systolic pressure on echocardiogram, if available) * Acute renal failure or chronic kidney disease * Platelets \< 100,000/uL * International normalized ratio (INR) \> 1.5 * Use of anticoagulant therapy that cannot be held for 2 days * Use of antiplatelet therapy (other than baby aspirin) that cannot be held for 5 days * Any bleeding diathesis * Pregnancy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • M D Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2023. Always confirm current availability with the study team.

View original record ↗